Novartis Ag (NVS) Acquisitions (2009 - 2025)
Novartis Ag recorded quarterly Acquisitions of -$21.0 million in Q4 2025, down 2200.0% quarter-over-quarter from $1.0 million in Q3 2025, and up 95.07% year-over-year from -$10.8 million in Q4 2024.
Novartis Ag's Acquisitions history runs 7 years deep, the most recent figure standing at -$21.0 million for Q4 2025.
- In Q4 2025, Acquisitions rose 95.07% year-over-year to -$21.0 million; the TTM figure through Dec 2025 stood at -$504.0 million (down 4.13% YoY), while the FY2025 annual figure was -$147.0 million, up 96.24% from the prior year.
- Acquisitions came in at -$21.0 million for Q4 2025 at Novartis Ag, down from $1.0 million in the prior quarter.
- In the past five years, Acquisitions ranged from a high of $1.0 million in Q3 2025 to a low of -$426.0 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 8.78 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 109.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 65.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -21.00 Mn |
| Sep 30, 2025 | 1.00 Mn |
| Dec 31, 2024 | -426.00 Mn |
| Sep 30, 2024 | -58.00 Mn |
| Dec 31, 2015 | -135.00 |
| Sep 30, 2015 | -228.00 |
| Jun 30, 2015 | -124.00 |
| Dec 31, 2014 | -350.00 |
| Sep 30, 2014 | -2.00 |
| Jun 30, 2014 | 114.00 |
| Mar 31, 2014 | -93.00 |
| Dec 31, 2013 | -32.00 |
| Sep 30, 2013 | -10.00 |
| Jun 30, 2013 | -32.00 |
| Mar 31, 2011 | -589.00 |
| Dec 31, 2009 | -35.00 |